Session » Pediatric Rheumatology – Clinical Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 2183

Accuracy of AI Tools for Diagnosis of Connective Tissue Disease

10:30AM-12:30PM: Abstract Number: 2176

Applying Similarity Network Fusion to Identify Patient Clusters for People with Systemic Inflammatory Disease

10:30AM-12:30PM: Abstract Number: 2194

Association of Reticular Dermis and Subcutis Inflammatory Infiltrate with Musculoskeletal Involvement in Pediatric Localized Scleroderma

10:30AM-12:30PM: Abstract Number: 2177

CD59 Complement Membrane Regulator Deficiency: 12 Years of Clinical and Molecular Follow-up of 29 Patients

10:30AM-12:30PM: Abstract Number: 2174

Current Treatment of Macrophage Activation Syndrome Worldwide: The METAPHOR Project, a PReS/PRINTO Real-life International Survey

10:30AM-12:30PM: Abstract Number: 2178

Evaluating the Non-Inferiority of Mycophenolate Mofetil Compared to Methotrexate in Treating Juvenile Localized Scleroderma

10:30AM-12:30PM: Abstract Number: 2179

Evaluation of Diagnostic Concordance Between Telehealth Encounters and In-Person Follow-up Assessments in Pediatric Rheumatology

10:30AM-12:30PM: Abstract Number: 2202

Evolving Phenotypic and Genotypic Spectrum of Human ISG15 and USP18 Deficiencies

10:30AM-12:30PM: Abstract Number: 2204

Guidance for Stem Cell Therapy for Juvenile Systemic Sclerosis Patients

10:30AM-12:30PM: Abstract Number: 2173

Hope and Health in Adolescents with Chronic Musculoskeletal Pain

10:30AM-12:30PM: Abstract Number: 2196

Identifying Specific Criteria for Juvenile Systemic Sclerosis: A Comparison of Adult and Pediatric Ratings

10:30AM-12:30PM: Abstract Number: 2201

Immunodeficiency-Related Monogenic Autoinflammatory Diseases; Expanding Spectrum of Immunodysregulation Disorders

10:30AM-12:30PM: Abstract Number: 2207

Improvement Across Physician and Patient Reported Outcome Measures over a 24 Months-time Period in the Juvenile Systemic Scleroderma Inception Cohort

10:30AM-12:30PM: Abstract Number: 2181

Large Pediatric Cohort with ANCA-associated Vasculitis at a Single Institution: Patient Characteristics, Clinical Course, and Outcomes

10:30AM-12:30PM: Abstract Number: 2184

Loss to Follow up After Transfer from Pediatric to Adult Care in Patients with JIA or jSLE

10:30AM-12:30PM: Abstract Number: 2189

Migratory Arthritis in Children: What Besides Rheumatic Fever?

10:30AM-12:30PM: Abstract Number: 2199

Mycobacterial Infection and Renal and Bladder Malignancy in 2 IFNopathy Patients on High Doses of JAK Inhibitors

10:30AM-12:30PM: Abstract Number: 2191

Optimizing Inpatient Kawasaki Disease Care

10:30AM-12:30PM: Abstract Number: 2197

Outcome Measures for the Assessment of Cutaneous and Musculoskeletal Manifestations of Juvenile Systemic Sclerosis: An International Collaborative Scoping Review and Survey of Current Practice

10:30AM-12:30PM: Abstract Number: 2187

Outcomes Following Tonsillectomy in Children with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome

10:30AM-12:30PM: Abstract Number: 2188

Parent Verses Patient Perspectives of Health-Related Quality of Life Among Children with Vasculitis

10:30AM-12:30PM: Abstract Number: 2182

PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results

10:30AM-12:30PM: Abstract Number: 2175

Pediatric Rheumatology Clinic Referral Patterns at a Large Midwestern Center

10:30AM-12:30PM: Abstract Number: 2195

Pediatric Rheumatology Graduation: A One-Way Bridge to Adult Care?

10:30AM-12:30PM: Abstract Number: 2205

Presence of Nailfold Capillary Changes Correlates with More Severe Organ Involvement in Juvenile Systemic Scleroderma. Results of the Juvenile Scleroderma Inception Cohort

10:30AM-12:30PM: Abstract Number: 2193

Prospective Evaluation of Reactogenicity and Safety Following COVID-19 Vaccination in Children with a History of MIS-C

10:30AM-12:30PM: Abstract Number: 2198

Severe and Long-Term Outcomes of COVID-19 Infection and Vaccine Hesitancy and Adverse Events in Children with Pediatric Rheumatic Diseases: Insights from a COVID-19 Global Rheumatology Alliance Caregiver Survey

10:30AM-12:30PM: Abstract Number: 2180

The Association Between Age at Diagnosis and Patient-Reported Outcomes in Patients with Vasculitis

10:30AM-12:30PM: Abstract Number: 2203

The Association of Autoantibodies with Clinical Manifestations and Long-term Outcomes in Juvenile- and Adult-onset Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 2186

The Exploration of Secondary Amplified Musculoskeletal Pain Syndrome (AMPS) in Pediatric Patients with Rheumatologic Disease

10:30AM-12:30PM: Abstract Number: 2206

There Is No Difference in Major Organ Involvement Andantibody Pattern Between Diffuse and Limited Subtypejuvenile Onsetsystemic Scleroderma Patients

10:30AM-12:30PM: Abstract Number: 2185

TRACER: Transition to Adulthood Through Coaching and Empowerment in Rheumatology, a Feasibility Study

10:30AM-12:30PM: Abstract Number: 2190

Uncovering Inborn Errors of Immunity in Pediatric Rheumatology

10:30AM-12:30PM: Abstract Number: 2192

Utilizing Electronic Health Record Pre-Consultation Data to Create a Predictive Algorithm for Diagnosis of Chronic Pediatric Rheumatic Conditions

10:30AM-12:30PM: Abstract Number: 2200

Whole Blood Transcriptome Profiling in Juvenile Systemic Sclerosis Patients Reveals Active Immune Upregulation and Enhanced Fibrotic Signature

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].